Joanna Sadowska: Bayer’s Asundexian Reduces Ischemic Stroke Risk in Phase 3 Trial
Joanna Sadowska, Biopharma Account Specialist, shared on LinkedIn:
”Big News – Bayer’s asundexian reduces ischaemic stroke risk in Phase 3 clinical trial
Bayer has announced positive Phase 3 results from the OCEANIC-STROKE study evaluating asundexian, an investigational once-daily oral Factor XIa inhibitor, for secondary stroke prevention.
This is the first study that successfully completed Phase 3 for Factor XIa.
Approximately 12 million people worldwide experience a stroke each year, with 20-30% being recurrent strokes.
One in five stroke survivors will have another stroke within five years, and these recurrent strokes tend to be more disabling and carry a higher mortality risk than first strokes.
Asundexian is a direct Factor XIa inhibitor designed to reduce thrombus formation that can lead to vessel blockage.
It has a novel mechanism targeting the coagulation pathway differently from current antiplatelet therapies.
Asundexian has received FDA Fast Track Designation for stroke prevention in this patient population.”
Stay informed with Hemostasis Today.
-
Jan 16, 2026, 13:15Paul Bolaji Invites You to Join World Stroke Organization Membership
-
Jan 16, 2026, 12:59Prithu Sundd on The Role of CD39 Polymorphism in Enabling Pulmonary Thrombosis in SCD
-
Jan 16, 2026, 12:46Gregory Piazza on The Effect of Enduring Risk Factors in Provoked VTE
-
Jan 16, 2026, 12:33Fernando Corrales-Medina on Heavy Periods in Teens: Don’t Miss a Bleeding Disorder
-
Jan 16, 2026, 06:05Wolfgang Miesbach on Jacob Lund’s Study: How to Define FVIII Bioequivalence
-
Jan 16, 2026, 05:52Piotr Czempik Shares His Latest Contribution to Acta Haematologica Polonic
-
Jan 16, 2026, 05:44Florian Piekarski on Perioperative Blood Management When Allogeneic Transfusion is Not Aaccepted
-
Jan 16, 2026, 05:00Plaque Rupture and Thrombosis
-
Jan 16, 2026, 04:52Arterial Disease Across Vascular Beds․ Lipoprotein(a) as a Causal Risk Factor